Interesting Institutes like Mount Sinai are run
Post# of 148109
(Total Views: 722)
Posted On: 09/02/2024 10:34:55 AM
Re: biloxiblues #146081
Interesting
The HIV drugs they're trialing are the anti-virals Truvada and maraviroc in two seperate arms. Truvada has shown benefit in an active Covid infection but thee only way I can see it working in Long Covid is as an immunosuppressant which is not ideal. Maraviroc would work like leronlimab with less effect.
HealthBio is Patterson's company. Why use a statin that lowers cholesterol and triglycerides when a true CCR5 blockade drug lowers cholesterol and triglycerides? Because maraviroc is an allosteric inhibitor that changes the shape of the CCR5 receptor to keep HIV and chemokines from binding to it, High levels of cholesterol lower maraviroc's ability to bind to CCR5 so a statin would be necessary to try and raise the binding ability.
Allosteric inhibitors are imperfect in their ability to bind and block. Maraviroc is superior to earlier CCR5 drugs like aplaviroc which only block HIV and one chemokine but is inferior to a competitive inhibitor like leronlimab which occupies the actual chemokine binding sites. Since leronlimab actively binds to CCR5 it can go about the work of lowering cholesterol and triglycerides without worrying about cholesterol lowering it's binding efficiency. It's no wonder that Patterson tried to hijack our patent.
They're ignoring our Long Covid trial so things can't be that urgent.
Quote:
Institutes like Mount Sinai are running clinical trials on repurposed HIV drugs.
https://www.okdoomer.io/beyond-paxlovid-the-u...tter-meds/
The HIV drugs they're trialing are the anti-virals Truvada and maraviroc in two seperate arms. Truvada has shown benefit in an active Covid infection but thee only way I can see it working in Long Covid is as an immunosuppressant which is not ideal. Maraviroc would work like leronlimab with less effect.
Quote:
So is HealthBio, a startup working on immune diseases. (They're testing maraviroc and atorvastatin.)
HealthBio is Patterson's company. Why use a statin that lowers cholesterol and triglycerides when a true CCR5 blockade drug lowers cholesterol and triglycerides? Because maraviroc is an allosteric inhibitor that changes the shape of the CCR5 receptor to keep HIV and chemokines from binding to it, High levels of cholesterol lower maraviroc's ability to bind to CCR5 so a statin would be necessary to try and raise the binding ability.
Allosteric inhibitors are imperfect in their ability to bind and block. Maraviroc is superior to earlier CCR5 drugs like aplaviroc which only block HIV and one chemokine but is inferior to a competitive inhibitor like leronlimab which occupies the actual chemokine binding sites. Since leronlimab actively binds to CCR5 it can go about the work of lowering cholesterol and triglycerides without worrying about cholesterol lowering it's binding efficiency. It's no wonder that Patterson tried to hijack our patent.
Quote:
As Harvard economist David Cutler has said on developing treatments for Long Covid, "There is no amount that's overdoing it." We're talking about a $16 trillion crisis.
We're talking about an urgent need for dozens of expedited clinical trials for drugs that already exist, which have shown effectiveness in preventing and treating Long Covid in its various incarnations. We're talking about making those drugs accessible right now for off-label use, so that Covid survivors can finally get the help they need.
They're ignoring our Long Covid trial so things can't be that urgent.
(23)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼